Evidence map›Paper›PMID 25995614›Full record

ArticleDrug design, development and therapy2015

Ultrasound contrast agent loaded with nitric oxide as a theranostic microdevice.

Dmitry Grishenkov, Adrian Gonon, Eddie Weitzberg, Jon O Lundberg, Johan Harmark, Barbara Cerroni, Gaio Paradossi, Birgitta Janerot-Sjoberg

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Ultrasonic technologies in imaging and drug delivery.Cellular and molecular life sciences : CMLS · 2021
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Dmitry GrishenkovDepartment of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden ; Department of Medical Engineering, KTH, Royal Institute of Technology, School of Technology and Health, Stockholm, Sweden ; Department of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.
Adrian GononDepartment of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden ; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Eddie WeitzbergDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Jon O LundbergDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Johan HarmarkDepartment of Biosciences and Nutrition, Karolinska Institutet, KTH, Royal Institute of Technology, School of Technology and Health, Stockholm, Sweden.
Barbara CerroniDepartment of Chemical Sciences and Technologies, University of Rome Tor Vergata, Rome, Italy.
Gaio ParadossiDepartment of Chemical Sciences and Technologies, University of Rome Tor Vergata, Rome, Italy.
Birgitta Janerot-SjobergDepartment of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden ; Department of Medical Engineering, KTH, Royal Institute of Technology, School of Technology and Health, Stockholm, Sweden ; Department of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.
Karolinska Institutet · SEKTH Royal Institute of Technology · SEUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current study describes novel multifunctional polymer-shelled microbubbles (MBs) loaded with nitric oxide (NO) for integrated therapeutic and diagnostic applications (ie, theranostics) of myocardial ischemia. We used gas-filled MBs with an average diameter of 4 μm stabilized by a biocompatible shell of polyvinyl alcohol. In vitro acoustic tests showed sufficient enhancement of the backscattered power (20 dB) acquired from the MBs' suspension. The values of attenuation coefficient (0.8 dB/cm MHz) and phase velocities (1,517 m/s) were comparable with those reported for the soft tissue. Moreover, polymer MBs demonstrate increased stability compared with clinically approved contrast agents with a fracture threshold of about 900 kPa. In vitro chemiluminescence measurements demonstrated that dry powder of NO-loaded MBs releases its gas content in about 2 hours following an exponential decay profile with an exponential time constant equal to 36 minutes. The application of high-power ultrasound pulse (mechanical index =1.2) on the MBs resuspended in saline decreases the exponential time constant from 55 to 4 minutes in air-saturated solution and from 17 to 10 minutes in degassed solution. Thus, ultrasound-triggered release of NO is achieved. Cytotoxicity tests indicate that phagocytosis of the MBs by macrophages starts within 6-8 hours. This is a suitable time for initial diagnostics, treatment, and monitoring of the therapeutic effect using a single injection of the proposed multifunctional MBs.

Indexed as

Theranostic NanomedicineChemistry, PharmaceuticalContrast MediaEquipment and SuppliesGasesHumansIn Vitro TechniquesMacrophagesMicrobubblesMyocardial IschemiaNitric OxideParticle SizePhagocytosisPowdersUltrasonicsContrast MediaGasesNitric OxidePowderscontrast agentmicrobubblesmyocardial ischemianitric oxideultrasound

Identifiers

PMID25995614
PMCPMC4425237
OpenAlexW1939475985

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.